initial public offerings (IPOs) trading on American exchanges

Saturday, January 25, 2014

Relypsa (RLYP) began trading on the NASDAQ on 15 November 2013

1/24/14 update
Jan 2014

Nov 2013


Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company has completed its two-part pivotal Phase III trial of its product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. The Company has designed patiromer to efficiently bind and remove potassium from the body, thereby treating hyperkalemia. The Company has conducted a clinical development program, in which daily administration of patiromer has been observed by the Company to lower, and maintain control of, serum potassium levels in hyperkalemic subjects with an acceptable safety and tolerability profile.


700 Saginaw Drive
United States 

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-314.24%-92.43%
Return on average equity--

No comments:

Post a Comment